List of Hysingla Er drug patents
Hysingla Er is owned by Purdue Pharma Lp.
Hysingla Er contains Hydrocodone Bitartrate.
Hysingla Er has a total of 24 drug patents out of which 1 drug patent has expired.
Expired drug patents of Hysingla Er are:
- US8529948
Hysingla Er was authorised for market use on 20 November, 2014.
Hysingla Er is available in tablet, extended release;oral dosage forms.
Hysingla Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate.
The generics of Hysingla Er are possible to be released after 21 December, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8529948 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(5 months ago) | |
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(4 months from now) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(4 months from now) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(9 months from now) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(9 months from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9861584 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9872837 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9572779 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9750703 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US8808740 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic